期刊
RADIOTHERAPY AND ONCOLOGY
卷 90, 期 3, 页码 413-421出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2008.10.021
关键词
Celecoxib; Ionizing radiation; Prostate cancer; Apoptosis; Bax
资金
- Deutsche Krebshilfe/Mildred-Scheel-Stiftung [10-1970 Be-III]
- Federal Ministry of Education and Research [Fo. 01KS9602]
- Interdisciplinary Center of Clinical Research Tubingen (IZKF) [1398-0-0]
Background and purpose: The cyclooxygenase-2-inhibitor celecoxib has been shown to inhibit cell growth and to reduce prostatic intraepithelial neoplasia in mice. The drug Was suggested to increase efficacy of ionizing radiation. However, extent and mechanisms of the Suggested benefit of celecoxib on the radiation response are still unclear. The aim of the present study was to analyze cytotoxic efficacy of celecoxib in combination with irradiation on human prostate cancer cell lines and to define the importance of proapoptotic Bax in this process. Materials and methods: Induction of apoptosis and global and clonogenic cell survival upon irradation-(2-10Gy), celecoxib-(11-75 mu M) or combined treatment were evaluated in prostate cancer cells by fluorescence microscopy, WST-1 assay and standard colony formation assays. Results: Celecoxib <25 mu M caused morphological changes and growth inhibition without substantial apoptosis or radiosensitization in terms of decreased clonogenic cell survival. In contrast, celecoxib >= 25 mu M increased radiation-induced cell death and clonogenic kill. While radiation-induced clonogenic death was increased in the presence of Bax, effects of celecoxib or combined treatment were Bax independent. Conclusions: Our findings reveal Bax-independent beneficial effects of celecoxib on radiation-induced apoptosis and eradication of clonogenic prostate cancer cells in vitro providing a rationale for clinical evaluation of high-dose celecoxib in combination with irradiation in prostate cancer patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 90 (2009) 413-421
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据